

Subject index

(Numbers cited are abstract numbers)

A

- α -Galactosylceramide 656
- ABVD therapy 241, 244, 247, 249, 371, 555, 591, 600
- ABVD/OPP therapy 555
- Activated cytotoxic T-lymphocytes 91
- Activated T-cells 175
- Acute haematological toxicity 248
- Acute lymphoblastic leukemia 348
- ACVB 194, 427
- Adjuvant therapy 259, 384
- Adnexal involvement 492
- Adryamicin 382
- Adult Hodgkin's disease 583
- Adult lymphoblastic lymphoma 63
- Advanced CLL 225
- Advanced diffuse large cell lymphoma 189
- Advanced high grade non-Hodgkin's lymphoma 610
- Advanced Hodgkin's disease 59, 61, 244, 245, 248, 560, 561, 586, 592
- Advanced indolent lymphoma 476
- Advanced low grade non-Hodgkin's lymphoma 449, 459
- Advanced non-Hodgkin's lymphoma 492, 653
- Advanced stage aggressive lymphoma 374
- Advanced stage diffuse large cell lymphoma 181, 425
- Advanced stage Hodgkin's disease 555, 576, 577
- Advanced stage low grade lymphoma 219
- Age-related treatment 243, 253, 397
- Aggressive chemotherapy 392
- Aggressive head and neck non-Hodgkin's lymphoma 386
- Aggressive intermediate high grade non-Hodgkin's lymphoma 629
- Aggressive localized lymphoma 184
- Aggressive lymphoma 265, 374, 382, 402, 403, 416
- Aggressive mantle cell lymphoma 191
- Aggressive non-Hodgkin's lymphoma 36, 87, 115, 166, 179, 182, 186, 194, 196, 198, 262, 267, 274, 344, 372, 373, 378, 379, 384, 385, 388, 393, 394, 395, 399, 408, 412, 599, 600, 601, 619, 623, 628
- Agricultural exposure 47
- ALK expression 129
- ALK lymphomas 89
- ALK oncogene expression 118
- Allelic imbalance 155
- Allogeneic bone marrow transplantation 111, 112
- Allogeneic transplantation 110
- Allografting 261
- All trans retinoic acid 359
- All-type therapy 79
- Alterations in DNA sequences 145
- Alternating MOPP/ABVD chemotherapy 244
- Anaplastic large cell lymphoma 80, 82, 90, 118, 129, 174, 346, 377, 407, 430, 530, 654
- Angiogenic growth factors 169
- Angio-immunoblastic T-cell lymphoma 130
- Angiolymphoid hyperplasia 93
- Animals 117
- Antibody levels 117
- Anti-CD20 antibody 568, 622
- Anti-CD20 antibody IDEC C2B8 11, 212, 658
- Anti-CD20 monoclonal antibody therapy 210, 224, 658
- Anti-CD25 565
- Anti-CD30 immunotoxin 106, 655
- Anti-*Helicobacter* therapy 70
- Anti-*Helicobacter pylori* treatment 229
- Antiproliferative effects 141
- Antisense oligonucleotide therapy 22, 113
- Antiviral therapy 38, 646
- Antracycline containing regimen 473
- Apoptosis 50, 58, 167, 366, 477, 478, 558
- Apoptosis-related proteins 326
- Apoptotic effects 141
- Arabinoside 609
- Ara-C 396, 635
- Argentina 120
- ASCT 629
- Asymmetric collimation 282
- Ataxia-telangiectasia 439
- ATM deletion 162
- ATM gene 20
- ATM heterozygosity 243
- Attained age 243
- Autografting 256, 261, 617
- Autoimmune diseases 165
- Autoimmune hemolytic anemia 322, 508
- Autoimmunity 365
- Autologous blood stem cell transplantation 597
- Autologous bone marrow transplantation 225
- Autologous haemopoietic cell transplantation 610
- Autologous haemopoietic progenitor cell support 260
- Autologous lymphocytes 100
- Autologous peripheral blood progenitor cell transplantation 274
- Autologous peripheral blood stem cell transplantation 600, 607, 641
- Autologous peripheral stem cell transplantation 42, 634
- Autologous stem cell support 62, 638
- Autologous stem cell transplantation 63, 72, 188, 239, 240, 258, 262–264, 266, 269–271, 551, 580, 594, 605, 606, 611, 613, 626–628, 630, 643, 644
- Autologous transplantation 608, 620, 639
- Autotransplant 238, 603
- AZA-anthracedione 653

B

- β -integrin expression 161
- B-7 molecules 351
- BBR2778 653
- BCAVi 592
- B-cell chronic disorders 160, 351
- B-cell chronic lymphocytic leukemia 157, 224, 341, 456, 461, 478
- B-cell cutaneous lymphoma 55

B-cell differentiation 175
 B-cell diffuse intermediate lymphoma 383
 B-cell diffuse large-cell lymphoma 88, 168
 B-cell lymphoma 17, 19, 76, 84, 136, 347, 666
 B-cell lymphoproliferative disorders 304, 316
 B-cell malignant lymphoproliferative disorders 471
 B-cell neoplasms 58
 B-cell non-Hodgkin's lymphoma 137, 162, 256, 288, 338, 363
 B-cell purged autotransplantation 604
 B-cell signalling complex 6
 B-cellular chronic lymphoid leukemia 321
 B-chronic lymphocytic leukemia 332, 367
 BCL-2 expression 167, 168, 247, 315, 343, 345, 359
 BCL-2 gene message 22
 BCL-2/IgH rearrangements 214, 369
 BCL-2 insertion 23
 BCL-2 oncogene 208
 BCL-2 protein 291, 297
 BCL-6 30
 BCL-6 gene hypermutations 135
 BCL-6 mutations 345, 349, 369
 BCL-6 proto-oncogene 337
 BCL-10 gene abnormalities 19
 BCNU 396, 635
 BCR-induced death 31
 BEACOPP chemotherapy 61, 576, 577
 Beam autotransplant 237
 Bendamustine 447, 452, 453, 458, 478, 479
 BIK/NBK-1 167
 Bilateral threphine biopsy 279
 Biologic features 158
 Biological markers 255
 Biological prognostic factors 36, 163
 BL60 cells 31
 Bleomycin 245, 589
 B-lineage chronic lymphoid malignancies 608
 Blood cell transplantation 112
 B lymphocyte-specific leukemia 350
 B lymphoproliferative disorders 171
 Body composition
 Bone marrow particles 4, 295
 Bone marrow transplantation 111, 112, 200
 Bone mineral density 246
 BOP 449
 Breakpoint analysis 148
 Breast cancer 243, 261
 Brief chemotherapy 180
 BuCyVP16 644
 Bulky disease 244
 Bulky Hodgkin's disease 560
 Bulky mediastinal Hodgkin's disease 571
 Burkitt's lymphoma 77, 120, 272, 370
 Burkitt's lymphoma cell 366
 Burkitt-like lymphoma 77
 Busulfan 597
 BVAM therapy 491
 BW5147 656

C
 CAMBO-VIP 374
 Carboplatin 240
 Cardiac function assessment 574
 Cardiac toxicity 636
 Caspase activation 136
 Caspase-8 mutations 153
 Castleman's disease 142, 670
 CC3 expression 152
 CCND1 171
 CD4-lymphopenia 445
 CD8-positive T-cell phenotype 94
 CD10 expression 543
 CD19+ selection 608
 CD20 antibody 609
 CD20 expression 104, 222
 CD23 466
 CD23 positivity 456
 CD25a cell cycle 166
 CD25b2 cell cycle 166
 CD30+ 407
 CD30 interaction 566
 CD30 ligand 566
 CD30 receptor 106, 152, 164, 174
 CD30 negative B-lymphocytes 172
 CD34+ blood stem cell transplantation 622
 CD34+ cells 214, 609
 CD34+ selection 608
 CD40 transgenic mice 364
 CD40L expression 568
 CD43 expression 316, 543
 CD44 expression 286
 CD56 lymphoma 125, 190, 300
 CD75 expression 543
 CD79b expression 316
 CD81 6
 CD95(FAS)-expression 165
 CDKN2 deletion 333
 CDRIII-PCR 338
 Celiac disease 132
 Cell apoptosis 332
 Cell compartments 214
 Cell death 367
 Cell proliferation 332
 Cell surface antigens 139
 CENP-F expression 355
 Central lymphatic irradiation 208
 Central nervous system infiltration 419
 Central nervous system relapse 43
 Centroblasts 28
 Centrocytes 28
 Centrofocal non-Hodgkin's lymphoma 533
 CEOP 193
 Cerebral large cell non-Hodgkin's lymphoma 415
 CEVOP-B 399
 Chemo-radiotherapy 391, 422, 440, 483, 484, 536, 538
 Chemo-resistant diffuse large B-cell lymphoma 277
 Chemosensitive diffuse large B-cell lymphoma 277
 Chemosensitive patients 131

Chemotherapy intensification 108
 Childhood acute lymphoblastic leukemia 441
 Childhood advanced Hodgkin's disease 443
 Childhood advanced-stage T-cell lymphoblastic lymphoma 441
 Childhood anaplastic large cell lymphoma 81, 83, 206
 Childhood B-cell lymphoma 205, 431, 435
 Childhood B-lymphoma 444
 Childhood gastric B-cell lymphoma 436
 Childhood HIV infection 437
 Childhood Hodgkin's disease 73-75, 440
 Childhood intestinal non-Hodgkin's lymphoma 434
 Childhood large cell lymphoma 438
 Childhood lymphoblastic lymphoma 78, 79, 202
 Childhood lymphoma 442
 Childhood Ki1 ALCL
 Childhood malignancies 433
 Childhood mediastinal large B-cell lymphoma 203
 Childhood mediastinal non-Hodgkin's lymphoma 432
 Childhood non-Hodgkin lymphoma 204
 Childhood small non-cleaved cell lymphoma 438
 Chimeric anti CD-20 monoclonal antibody 482
 China 135
 Chlorambucil 70, 228, 245
 2-chloro-2'-deoxyadenosine 471, 526, 659
 CHLVPP/EVA hybrid regimen 59
 CHOD 481
 CHOP therapy 64, 179, 195, 196, 201, 266, 270, 274, 371, 380, 382, 389, 394, 418, 427, 600
 CHOP-like therapy 198
 Chromosomal breakage syndrome 204
 Chromosomal imbalances 356
 Chromosome 13 deletion 44
 Chromosome aberrations 157, 172
 Chromosome translocations 26, 29
 Chronic B-cell leukemia 144, 226
 Chronic gastritis 543
 Chronic lymphadenitis 368
 Chronic lymphocytic leukemia 72, 100, 111, 139, 222, 227, 228, 352, 353, 360, 454, 457, 464, 466, 471, 479
 Chronic lymphoproliferative disorders 475
 CHVmp/BV 66
 Circulating T-cells 165, 212, 218
 Cisplatin 375, 378, 470, 663
 Cladribine 445, 455, 471, 526, 659
 Classical Hodgkin's disease 5, 172
 Clinical evaluation 394
 Clinical features 158, 235
 Clinical research 236
 Clonal loss of heterozygosity 138
 Clonally expanded T lymphocytes 361, 544
 CML cells 141
 CNOP therapy 193, 196
 CNS involvement 329, 491, 530
 CNS prophylaxis 410
 CNS relapse 420
 CTCL diagnosis 511
 COA regimen 451
 Coeliac disease 529
 Collection efficiency 609
 Combined modality therapy 251, 384
 Comperative genomic hybridization 10, 145, 154
 Complete remission 624, 640
 Computer tomography 318, 571
 Conformal radiotherapy 285
 Consolidative treatment 265, 640
 Continous infusional chemotherapy 388
 COP 449
 COPA regimen 181
 Corticosteroid-resistant T-lymphoma cells 167
 Cost-effectiveness 620
 I.CR 272
 CT scans 51, 314
 CTL responses 170
 Cure probability 254, 623
 Cutaneous B-cell lymphoma 486
 Cutaneous involvement 296
 Cutaneous lymphoma 14, 54, 55
 Cutaneous T-cell lymphoma 27, 94, 147, 152, 515
 CVP chemotherapy 217, 220
 CVPP 563
 Cyclin D1 171
 Cyclin dependent kinase 6 21
 Cyclin E expression 355
 Cyclophosphamide 22, 219, 223, 228, 382, 414, 424, 429, 461, 462, 471, 480, 563, 597, 612, 636, 641, 642
 Cytarabine 375
 Cytogenetic aberrations 404
 Cytogenetic analysis 128, 142, 154, 342, 344
 Cytokine profiles 32, 569, 588, 613
 Cytokine-release syndrome 224
 Cytogenetic characterisation 442
 Cytoreduction 240, 469
 Cytosine 609
 Cytotoxic chemotherapy 246, 461
 Cytotoxic proteins 514
 CXCR3 160

D

Daunoxome 429
 Dermatology 56
 Dexamethasone 211, 378, 396, 635
 DHAP treatment 270
 Diagnosis of lymphoma 279
 Diethylhomospermine 105
 Diffuse large B-cell lymphoma 64, 88, 135, 151, 156, 163, 176, 180, 263, 291, 315, 317, 345, 404
 Diffuse large cell lymphoma 35, 180, 183, 199, 200, 277, 289, 368, 417, 423, 427, 596, 620
 Diffuse large cell non-Hodgkin's lymphoma 409
 DNA amplifications 356
 Dose-escalated chemotherapy 267
 Dose-intensified chlorambucil 228
 Dose-intensity 12, 397, 427
 Doxorubicin 223, 245, 359, 402, 657
 Double autotransplant 265

Drug-induced cell death 367
Drug-induced apoptosis 167
Drug-resistant chronic lymphocytic leukemia 360

E

Early death 194
Early stage Hodgkin's disease 249
Early stage primary extranodal lymphoma 540
EBV-negative PEL 522
EBV-related lymphoproliferative disorders 664
EBVP/MV therapy 589
ECHOP-B regimen 383
Economic G-CSF-support 394
Egypt 372, 373, 380, 434
Elderly patients 65, 108, 178, 181, 182, 189, 198, 199, 380, 385, 389, 392, 395, 408, 413, 414, 418, 423, 426, 428, 463, 573, 576, 579, 618
Elevated antibody levels 118
EMP-salvage therapy 668
Endostatin 169
Engraftment 613
Enteropathy associated T-cell lymphoma 505
Enteropathy-type intestinal T-cell lymphoma 235
Environmental risk factors 308
EORTC classification 53
Eosinophilia 93, 134, 578
Eotaxin receptors 152
EpiADM 399
Epidemiology 46
Epirubicin 381, 414, 424, 454, 589, 594, 636
Epithelioid granulomas 281
Epitopes 170
EPOCH therapy 179
Epstein-Barr virus 2, 3, 5, 38, 117, 120, 120a, 348, 569, 585, 646
Eradication 230
Etiology of lymphoma 308
Etoposide 240, 245, 378, 381, 396, 400, 414, 452, 470, 589, 594, 612, 635, 642
Event-free survival 614
EVEP therapy 572
Exhaust 117
Extended field radiation 250, 282, 572
Extra biopsy specimens 304
Extranodal DLBCL 135
Extranodal Hodgkin's lymphoma 237
Extranodal lymphocytic infiltrates 365
Extranodal lymphoma 236
Extranodal non-Hodgkin's lymphoma 153, 237

F

FADD expression 136
Failure free survival 69, 247
Failure patterns 213, 234
Familial PMLCL 665
Family history 47
FAS 300
FAS-ligand 300
FAS-mediated cell death 367
FAS-mediated apoptosis 136
FAS mutations 153

18 FDG-pet 51
FDG-PET 122, 299
Feasibility 256, 576, 618
FGFR3 354
Fiber fish 343
Field irradiation 60
Fibroblasts 134
Field radiation 250
Fine needle 294
First line treatment 42, 205, 271, 629
FISH analysis 144, 157
Flavopiridol 141
Flow cytometry 304, 310
Fludarabine 211, 217, 219-221, 223, 375, 454, 457, 459, 462, 476, 480, 481, 508
Fludarabine combination therapy 227, 228, 461, 463, 474
Fludarabine phosphate 652
Fluorescence *in situ* hybridization 154
F-MACHOP 416, 629
Follicle centre cell lymphoma 176
Follicular dendritic cell like cell line 328
Follicular lymphoma 23, 34, 67, 68, 102, 103, 149, 208, 209, 211-214, 216, 218, 258, 291, 342, 343, 349, 359, 369, 421, 462, 469, 472, 473, 477, 543, 598, 611, 622, 631
Follicular lymphoma cell line 328
Follicular mycosis fungoides 542
Follicular non-Hodgkin's lymphoma 207, 319, 460, 605
Foscarnet 646
Framework derived sequences 170
France 192, 205, 298, 421
Front line chemotherapy 237, 266, 614, 641
Front line patients 227
Functional expression 159

G

Gallium scan 131, 312
Gallium-67 scintigraphy 314, 318
Gastric B-cell lymphoma 436
Gastric lymphoma 155, 231, 232, 233, 506, 545
Gastric MALT lymphoma 1, 229, 524, 527
Gastric non-Hodgkin's lymphoma 535
Gastritis 165
Gastroenteropathy 494
Gastrointestinal involvement 191
Gastrointestinal malignancies 253
Gastrointestinal non-Hodgkin's lymphoma 541, 547
G-CSF 427, 627, 641
Genescan analysis 338
Genetic imbalances 150
Gene therapy 114
Genotyping 146
Germany 228, 402
Germinal center development 28, 30, 31
Graft-versus-malignancy 110, 593
Granulomatous slack skin 493
Growth fraction 294

H

H-RS cells 154

Haematological malignancies 116

Haematological toxicity 248

Hairy cell leukemia 117

Harvest 108, 627

Harvest purity 613

Head and neck cancer 287, 540

Helicobacter pylori infection 230, 524

Hematological malignancies 325

Hematological neoplasia 261

Hematopoietic cells rescue 268

Hematotoxicity 186

Hemopathology biopsies 310

Hepatosplenic $\Upsilon\gamma\delta$ -non-Hodgkin's disease 517

Hepatic toxicity 320

Hepatitis B virus infection 288, 630

Hepatitis C virus infection 6, 121, 288, 320, 630

Hepatitis G virus 358

Hepatosplenic $\gamma\lambda$ t-cell lymphoma 92, 124

Heterozygosity 138, 156

HHV-8 genes 4, 522

High-dose chemotherapy 45, 68, 214, 225, 239, 240, 256–258, 260, 262, 266, 269, 270, 272, 551, 580, 606, 619, 633

High-dose sequential chemotherapy 273

High grade B-cell gastric lymphoma 230, 507

High grade B-cell lymphoma 658

High grade B lymphoblastic lymphoma 437

High grade lymphoma 371

High grade malignant non-Hodgkin lymphoma 401, 405

High grade non-Hodgkin's lymphoma 65, 66, 178, 193, 195, 254, 266, 389, 391, 392, 397, 413, 414, 422, 428

High grade primary gastrointestinal B-cell lymphoma 173

High risk diffuse large cell lymphoma 641

High risk follicular non-Hodgkin's lymphoma 644

High risk lymphoma 603

High risk malignant non-Hodgkin's lymphoma 640

High risk post-transplant lymphoproliferative disorders 647

High tumor burden 611

Histological progression 210

Histological transformation 216

Histomorphological analyses 306

Histopathological features 232

HIV 12–14, 322, 133, 415

HIV-associated non-Hodgkin's lymphoma 105, 197

HIV-negative patients 536

HIV-negative PEL 522

HLA Class I expression 156

HLA Class II expression 156

HLA phenotypes 550

Hodgkin cells 134, 138, 247

Hodgkin-derived cell line 566

Hodgkin-like B-cell lymphoma 252

Hodgkin's disease 33, 60, 106, 122, 154, 238, 239, 241–245, 247–255, 305, 323, 549–592, 616, 626

HRBCL 84

HTLV-1 carrier 669

Human lymphoma cells 362

Hybrid-NOU therapy 561

Hyperfractionated radiotherapy 42

Hypersplenism 673

I

Idarubicin 221, 402, 426, 476, 632, 640

IDEC anti-CD20 antibody 648

IDEC-C2B8 482

IDEC-Y2B8 215

Ifosfamide 240, 378, 381, 594

IgH genes 363

IgH rearrangements 23, 345, 369

IL-1 concentrations 340

IL-2 receptor measurement 373, 474

IL-10 concentrations 323, 325

IL-4 concentrations 325

IL-6 concentrations 340

ILA 364

Imaging algorithm 489

Immunoblastic lymphoma 88

Immunoblastic non-Hodgkin's lymphoma 43

Immunocompetent patients 510

Immunocompromised hosts 329, 330

Immunogenetic analysis 151

Immunoglobulin 170, 24

Immunohistochemical analysis 569

Immunohistological analyses 306

Immunologic expression 289

Immunophenotypic changes 210

Immunophenotypic subclones 341

Immunosuppressed patients 662, 664

Immunotherapy 32, 101

Immunotoxins 564

India 120

Induction therapy 212, 239

INF- γ concentrations 324

Infection rate 659

Infectious risk factors 308, 643

Intensive CHOP-therapy 394

Intensive therapy 188, 191, 268, 409, 631

Interferon α 218, 222, 469

Interferon α 2b 188

Interferon- γ 104

Interleukin-2 445

Interleukin production 324

Intermediate-dose sequential chemotherapy 189

Intermediate grade lymphoma 371

Intermediate grade non-Hodgkin's lymphoma 43, 193, 195, 201, 389, 397, 400, 413, 414, 422, 428

Intermediate stage Hodgkin's disease 250

Intermediate risk diffuse large cell lymphoma 641

Intermediate risk non-Hodgkin's lymphoma 625

International Prognostic Index 67, 190, 231, 255, 393, 448, 468, 586

Interphase 343

Intestinal T-cell lymphoma 235

Intraclonal heterogeneity 151

Intramammary lymph node 276

Intramammary lymphoma 276

Intraocular lymphoma 268

In vitro exposure to interferon 222

In vivo purging therapy 259
Involved-field radiotherapy 242
Iodine-131 anti-B1 antibody 99, 448
IPI 427
IPI high risk therapy 266
IPI score 617
Irradiation 41
Israel 506
Italy 119, 183, 207, 271

J
Japan 115

K
Kaposi sarcoma 322, 503
Kaposi sarcoma Herpes virus 503
K1-1 (CD30) leukemia 667
K1-3(SCFV)-ETA 106
Ki-67 expression 140, 294, 567
Ki-67 nuclear proliferative antigen 291
Kiel classification 317
K-ras gene point mutations 368
Kuwait 562
Kyrgyzstan 432

L
Langerhans cell histiocytosis 552
Large cell anaplastic lymphoma 650
Large cell lymphoma 264, 420
Large T-cell transformation 499
Latent membrane protein 1 120a
LDH 668
Lenograstim 595
Leukemia 76, 114, 206
Leukemic bouts 326
Leukemic lymphocytosis 465
Leukopenia prognosis 549
Liposomal vincristine 107
Local control 391
Localized aggressive non-Hodgkin's lymphoma 115
Localized Hodgkin's disease 251
Localized primary gastric diffuse large B-cell lymphoma 231
Locoregional high-dose radiotherapy 528
Lomustine 419
Long distance PCR 370
Long term disease control 528
Long term outcome 273, 292, 407
Long term side effects 250
Long term survival 671
Low grade B-cell lymphoma 148, 658
Low grade follicular lymphoma 257
Low grade gastric B-cell lymphoma 165
Low grade gastric lymphoma 70
Low grade gastric MALT lymphoma 500
Low grade lymphoma 111, 604, 609
Low grade malignant lymphoma 451
Low grade non-Hodgkin's lymphoma 68, 100, 217, 221, 445, 446, 447, 450, 452, 455, 458, 460, 463, 468, 471, 474, 480
Low grade primary gastrointestinal B-cell lymphoma 173

Low-intermediate risk aggressive lymphoma 187
Lung injury 571
Lyme disease borrelias 485
Lymphadenopathy 290
Lymph node involvement 493, 578
Lymphoblastic lymphoma 272
Lymphoblastic lymphoma relapses 202
Lymphocyte predominance Hodgkin's disease 150
Lymphoid malignancies 260
Lymphoid microenvironment 324
Lymphoid tumor cells 159
Lymphoma among siblings 303
Lymphoma classification 15, 16
Lymphoma implants growth patterns 330
Lymphoma biomarkers 350
Lymphomagenesis 2
Lymphoma residual masses 299
Lymphoproliferative diseases 143, 322, 358, 365, 662

M
MACOP-B 201, 641
Macrophages 105
Magnetic resonance 314, 318
Male reproductive potential 575
Malignant B cells 160
Malignant lymphoma 50, 133, 275, 284, 355, 516, 621
MALT histology 545
MALT lymphoma 18, 488, 496, 500, 507, 524, 527, 531, 543, 547
Maltoma's malignancy 546
Management of lymphoma 127, 235, 486, 540
Manganese superoxide dismutase levels 433
Mantle cell lymphoma 20, 37, 101, 102, 110, 140, 141, 145, 146, 219, 269, 270, 296, 309, 353, 356, 376, 398, 596, 598, 622
Marginal zone B-cell lymphoma 128, 335
Marrow flow cytometry 311
Massive bone marrow involvement 599
Mast cells 566
Mature B-cell lymphoma 76
M-CHEP 459
MDR-1 protein expression 297
Mdm2 protein status 585
Median nerve 537
Mediastinal fine-needle aspiration biopsy 293, 294
Mediastinal Hodgkin's lymphoma 131
Mediastinal large B-cell lymphoma 203, 624
Mediastinal large cell lymphoma 580
Mediastinal lymphoma 318, 387
Mediastinal non-Hodgkin's lymphoma 432
Mediastinal T-cell lymphoblastic lymphoma 410
Mediastinum 283
MegaCEOP 424
Melphalan 396, 453, 632, 635, 640
MEMID 198
Metalloproteinase overexpression 329
Metastatic breast cancer 261
Methotrexate 41, 378, 589
Mexico 533–535
MIB-1 87
Microdissected cells 527

- Micromanipulation 361
 - Microsatellite instability 155
 - Microsatellite PCR 138
 - Microvessel density 277
 - Mini-allografting 261
 - Mini-CEOP 199
 - Mitoxantrone 211, 375, 455, 459, 461, 462, 474, 480, 609
 - MMset 354
 - Mobilised stem cell support 602
 - Model based development 394
 - Molecular biology 511
 - Molecular cytogenetic analysis 173
 - Molecular identification 276
 - Molecular pathogenesis 17
 - Molecular polymorphism 362
 - Molecular remissions 110
 - Molecular response rate 208
 - Molecular techniques 342
 - Molecular biological analyses 306
 - Molecular remissions 598
 - Molecular response 103
 - Monoclonal antibody 175, 294, 467
 - Monoclonal antibody therapy 210, 224
 - Monoclonal B-cells 527
 - Monoclonal gammopathies 581
 - Monoclonality 363
 - MOPP therapy 244, 592
 - Morocco 583
 - Morphological diagnosis 546
 - MRI 299
 - 99mTC-BerH2 650, 651
 - Mucosa-associated lymphoid tissue lymphoma 71, 148, 165, 436
 - Multiple isotype expression 151
 - Multiple myeloma 4, 44, 45, 104, 354, 453, 607, 643, 674
 - MUM1p 175
 - Murine cell line 364, 654, 655
 - Murine T-cell lymphoma 656
 - Mycosis fungoides 147, 361, 490, 499, 514, 526, 548
 - Myeloablative therapy 641
 - Myelodysplasia 260
 - Myeloid tumor cells 159
 - Myeloma 24, 141
- N**
- Nasal cavity 516
 - Nasal lymphoma 528
 - Neoplasms 283
 - Neoplastic cells 514
 - Neurocysticercosis 116
 - Neuropsychological evolution 513
 - Newly diagnosed patients 217
 - NK cell lymphoma 520
 - NK/T phenotype 528
 - Nodal anaplastic large cell lymphoma 91
 - Nodal cytotoxic lymphoma spectrum 278
 - Nodal diffuse large B-cell lymphoma 177, 390
 - Nodal DLBCL 135
 - Non-ablative autotransplant 238
 - Non-follicular low-grade lymphoma 465
 - Non-gastrointestinal low grade mucosa-associated lymphoid tissue 496
 - Non-Hodgkin's lymphoma 43, 46, 48, 58, 65, 66, 86, 99, 119, 161, 164, 169, 210, 259, 274, 280, 281, 286, 287, 292, 294, 297, 298, 305, 307, 311, 320, 323, 324, 339, 340, 344, 357, 419, 426, 494, 495, 529, 595, 617, 618, 627, 634, 636, 660, 672
 - Non-Hodgkin's lymphoma of the testis 539
 - Non-nasal aggressive NK cell lymphoma 300
 - Notch receptor pathways 3
 - No treatment 188
 - Novel tumor suppressor loci 137
 - NPM-ALK 174
- O**
- OPP therapy 555
 - Oral regimen 419
 - Orbital involvement 492
 - Organic solvents 117
 - Observation 70
 - Occupational risk factors 308
 - Overall survival 209, 408
- P**
- 6p 137
 - 6p21.3 156
 - 9p 25
 - p16 gene expression 357
 - p16^{INK4a} expression 147, 585
 - p27 gene expression 355
 - p53/BAX pathway 360
 - p53 gene expression 168, 291, 357, 567, 585
 - p53 mutation 390
 - p-80 immunoreactivity 82
 - PACEBOM 64
 - Paclitaxel 379
 - Panniculitis-like subcutaneous T-cell lymphoma 512
 - Paragranuloma-type TCRBCL 84
 - Paranasal sinuses 516
 - Parapsoriasis 306
 - Parenchymal lung 443
 - Parker & Jackson's tumor 509
 - Pathology study 85
 - PBPC autograft 272
 - PBPC mobilisation 108, 616
 - PBSC contamination 596
 - PBSC harvests 604
 - PBSC mobilisation 595
 - PBSC transplantation 259, 517
 - PCR 69, 362, 370
 - PCR analysis 363
 - Peripheral blood 544
 - Peripheral blood CD34+ hematopoietic stem cells 609
 - Peripheral blood dendritic cells 4
 - Peripheral blood lymphocyte subpopulations 659
 - Peripheral blood progenitor cell mobilisation 612
 - Peripheral blood progenitor cells 598
 - Peripheral blood stem cell support 257
 - Peripheral blood stem cell transplantation 623, 624
 - Peripheral T-cell lymphoma 130, 383, 669

- Persistent massive lymphoproliferation 439
- Pesticides 117
- PET scanning 127
- Phosphatases 166
- Plaques 306, 514, 544
- PLBCL 283
- Pneumocystis pneumonia 669
- Poland 206, 444
- Polyamine analgou therapy 105
- Polymerase chain reaction 208
- Polyvalent gammaglobulins 508
- Poor prognosis lymphoma 615
- Poor prognosis non-Hodgkin's lymphoma 271, 274, 424
- Poor risk aggressive lymphoma 265
- Poor risk Hodgkin's disease 238
- Poor risk non-Hodgkin's lymphoma 614
- Posttransplant lymphoproliferative disorders 7, 8, 10, 11, 123, 645–649
- Predictive factors 255, 319
- Prednisolone 245
- Prednisone 219, 223, 245, 382, 414, 429, 453, 471, 480, 563, 589, 642
- PreGC 350
- Preradiation therapy 525
- Pretreated patients 634
- Primary bone lymphoma 487, 489, 509
- Primary central nervous system lymphoma 192, 268
- Primary central nervous system lymphoma 40–42, 510, 525
- Primary cerebral lymphoma 39
- Primary CNC lymphoma 486, 510
- Primary cutaneous B-cell lymphoma 532
- Primary cutaneous CD30-positive lymphoproliferative disorders 126
- Primary cutaneous extranasal nasal-type CD56+ lymphoma 125
- Primary cutaneous lymphoma 53, 94, 125
- Primary cutaneous plasmacytoma 523
- Primary diffuse large B-cell lymphoma 624
- Primary effusion lymphoma 503, 522
- Primary gastric B-cell lymphoma 232
- Primary gastrointestinal lymphoma 233, 498
- Primary large B-cell lymphoma 283
- Primary large cell gastric lymphoma 521
- Primary MALT gastric lymphoma 531
- Primary mediastinal B-cell lymphoma 25
- Primary mediastinal large cell lymphoma 411, 665
- Primary nervous system lymphoma 38, 513, 536
- Primary non-Hodgkin's lymphoma 491
- Primary orbital lymphoma 519
- Primary progressive Hodgkin's disease 254
- Primary refractory aggressive non-Hodgkin's lymphoma 378
- Primary refractory disease 223
- Primitive cerebral lymphoma 538
- Primitive extranodal lymphoma 537
- Procarbazine 245, 419, 563, 642
- Prognostic discrimination 190
- Prognostic factors 158, 164, 168, 177, 185–187, 194, 200, 232, 233, 242, 244, 264, 287, 289, 291, 297, 391, 397, 403, 404, 408, 411, 446, 450, 456, 545, 578
- Prognostic score validation 586
- Prognostic systems 559
- Progressed variants of non-Hodgkin's lymphoma 357
- Progressive disease 606
- Prohylaxis 43
- Proliferation 477, 558
- Proliferative index 85, 315
- Prolonged therapy 610
- Promace-cytabom 197
- Protein expression 390
- Pseudomonas* exotoxin 655
- Psychosomatic aspects of Hodgkin's disease 556
- Pure extranodal lymphoma 534
- Purity 609
- Purged autologous bone marrow transplantation 225
- P-VABEC regimen 182
- P-VEBEC regimen 199, 423
- Pyvalyloxymethyl butyrate 657
- Q**
- 3q27 abnormalities 177
- 7q translocation 21
- 11q23.1 353
- 11q deletion 20, 139
- 12q12-14 176
- Quality of life 199, 246, 403, 412, 672
- Quantitative monitoring 218
- Quintuple approach 647
- R**
- Radiation 488, 549
- Radioactive monoclonal antibodies 98
- Radiochemotherapy 483
- Radioimmunotherapy 661
- Radiotherapy 60, 215, 242, 244, 249, 251, 384, 401, 411, 519, 528, 536, 553, 591
- Rb expression 168, 567
- Reactive lymphoid hyperplasia 143
- REAL classification 76, 86
- Real time PCR 218
- Recovery 627
- Recurrent low grade non-Hodgkin's lymphoma 220
- Reduced delivery of chemotherapy 579
- Reduced disease control 248
- Reed–Sternberg cells 5, 134, 138, 247
- Refractory B-cell chronic lymphoid malignancies 470
- Refractory Hodgkin's disease 62, 237, 240, 551, 558, 565, 594, 638
- Refractory indolent non-Hodgkin's lymphoma 448, 635
- Refractory low grade non-Hodgkin's disease 479, 481
- Refractory lymphoma 375, 381, 663
- Refractory non-Hodgkin's disease 185, 215, 379, 479, 623, 638, 642, 653, 668
- Refractory primary central nervous system lymphoma 268
- Refractory sprue 132
- Region radiotherapy 180
- Reinfusion 108
- Relapsed aggressive lymphoma 633, 637
- Relapsed chronic lymphocytic leukemia 462
- Relapsed cutaneous T-cell lymphoma 515
- Relapsed follicular lymphoma 216, 613
- Relapsed Hodgkin's disease 62, 109, 240, 551, 594, 638, 650
- Relapsed indolent B-cell lymphoma 482
- Relapsed indolent non-Hodgkin's lymphoma 448, 635

Relapsed low grade non-Hodgkin's disease 479, 481
 Relapsed lymphoma 612
 Relapsed lymphoma residual masses 299, 597
 Relapsed non-Hodgkin's disease 107, 185, 215, 379, 396, 429, 447, 479, 623, 638, 642, 668, 671
 Relapsed patients 227
 Relapsed primary central nervous system lymphoma 268
 Relapsing lymphoma 188, 375, 381
 Remission 513, 527
 Remission duration 659
 Remission in Hodgkin's disease 239
 Reovirus induced cell death 331
 Reproducibility of response 405
 Residual diseases 244
 Residual masses 51
 Resistant aggressive non-Hodgkin's lymphoma 637
 Resistant B-prolymphocytic leukemia 467
 Resistant chronic lymphocytic leukemia 462
 Resistant hematological neoplasia 261
 Resistant lymphoma 612
 Resistant non-Hodgkin's lymphoma 396
 Response criteria 660
 Response duration 209, 427
 Restaging 131
 Retinoblastoma protein 585
 Retinoids 52, 664
 Retroperitoneum 283
 Retrospective survival analysis 545
 Revised European-American lymphoma classification 280, 292
 Richter's syndrome 352, 457
 Richter's transformation 464
 Risk-adapted sequential combination chemotherapy 601
 Risk assessment 183
 Rituxan 613, 633
 Rituximab 11, 101, 102, 103, 104, 195, 210, 212, 224, 256, 259, 460, 465, 467, 472, 482, 609, 622, 648, 658, 661, 662
 RT + ASCT 629
 Russia 229, 550

S
 Salvage therapy 270, 375, 458, 642, 668
 Sandwich delivering of radiotherapy 571
 sCD30 concentrations 323
 Scid mice 22, 26, 167
 Sclerosis 203
 Scoring systems 226
 Secondary acute myelogenous leukemia 260
 Secondary cutaneous CD30-positive lymphoproliferative disorders 126
 Secondary non-Hodgkin's lymphoma 406
 Second line therapy 378
 Second malignancies 582
 Secrete eotaxin 134
 Selection bias 243
 Sequential FISH analysis 144
 Sequential therapy 601, 602, 607, 614, 617, 618, 623, 632, 638
 Serology 485
 Serum B-2 microglobulin 190
 Serum CA-125 levels 305
 Serum ferritin 275
 Serum IL-10 373
 Serum levels 158, 588
 Serum soluble interleukin-2 receptor levels 336
 Sézary syndrome 147, 490
 SFOP LMT 89 202
 Siblings 303
 Single-cell PCR 361
 Skin 544
 Skin electron irradiation 548
 Skin node involvement 493
 Slowly progressive lymphadenopathy 290
 Small cell lymphoma 353
 Small lymphocytic lymphoma 456, 598
 Small plaque parapsoriasis 544
 Solid allograft recipients 649
 Solid organ transplantation 645
 Solitary plasmacytoma 497
 Soluble CD30 164
 Soluble ICAM-1 158
 Soluble IL-2 373
 Soluble VCAM-1 158
 Spain 264, 284
 Splenectomy 475, 508
 Splenic irradiation 673
 Splenic lymphoma 21
 Splenic lymphoma with villous lymphocytes 121, 301
 Splenic marginal zone lymphoma 301
 Splenic rupture 674
 Staging of lymphoma 295
 Standard chemotherapy 66
 Standard staging procedures 122
 Stanford V regimen 560
 Stem cell autotransplantation 637
 Stem cell mobilisation 613
 Stem cell rescue 635
 Stem cell support 267, 615, 633
 Stem cell transplant 191
 Stomach lymphoma 488, 504
 Subcutaneous NK/T cell lymphoma 502
 Subtle Leydig cell dysfunction 246
 Surgical therapy 545
 Survival 85, 201, 209, 231, 391, 420, 427, 446, 545, 637, 668
 Survival selection 366
 Syndecan-1/CD138 362
 Systemic human cell lymphoma 22
 Systemic large cell non-Hodgkin's lymphoma 415

T
 t(4;14) concentration 354
 t(8;14)(q24;q32) translocation 370
 t(11;18)(q21;q21) 18, 148
 t(14;18) concentration 47, 212, 218, 342
 t(14;18)(q32;q21) 208
 T-cells 134
 T-cell cutaneous lymphoma 52, 55, 56, 57
 T-cell Hodgkin's lymphoma 49
 T-cell lymphoblastic lymphoma 79
 T-cell lymphoma 92, 124, 327

T-cell non-Hodgkin's lymphoma 337
 T-cell receptors 32
 T-cell rich large B-cell lymphoma 302, 313, 435
 T-lymphocyte proliferation 351
 Tandem autologous stem cell transplantation 109
 Tandem high-dose therapy 615
 Tandem transplants 44, 261
 TCL-1 oncogene expression 143
 Telomerase activity 147
 Testicular lymphoma 234, 518, 539
 Thymic reactive hyperplasia 584
 Thymidine kinase serum level 307
 TNF- α serum levels 339
 TNF receptor-associated factors 557
 Topotecan 400
 tolerability 199
 Topoisomerase II α expression 140
 Total body irradiation 270
 Toxicity 244, 273, 389, 425, 576, 591, 618
 TP53 expression 315
 TRAF2 557
 TRAF3 557
 TRAF5 557
 TRAIL 159
 Transformed variants of non-Hodgkin's lymphoma 357
 Treatment outcome 233
 Treatment planning 285
 Treatment resistance 366
 Trimetrexate 515
 Trisomy 12 144, 341
 TTP toxicity 623
 Tumor dissemination 161
 Tumor growth 167, 514
 Tumor load 604
 Tumor markers 327
 Tumor necrosis 3
 Tumor necrosis factor polymorphisms 149
 Tumor size 497
 Tumor suppressor genes 146
 Two-colour flow cytometry 321

U

Uganda 133
 Unconjugated monoclonal antibody therapy 95
 Unilateral biopsy 279
 United Kingdom 236, 245, 504, 505, 554
 Universal PCR 154
 Up-front therapy 274, 399

V

V β pohenotyp 327
 Vaccines 95
 VANDA protocol 202
 V(D)J recombinase 26, 29
 Venezuela 431
 VEPEMB regimen 573
 VH gene family utilization 347
 Villous lymphocytes 508
 Vinblastine 245, 563, 589
 Vincristine 245, 382, 414, 429
 Vincristine–adriamycine continous infusion 395
 Visceral involvement 82
 VNCOP-B 65, 178
 VP16 399

W

Waf-1 protein 567
 Waldenstrom's macroglobulinaemia 223, 301
 Waldeyer's ring lymphoma 484
 Waldeyer's ring non-Hodgkin's lymphoma 483, 501
 Whipple disease 290
 WHO classification 86
 Working formulation 280

Y

⁹⁰yttrium 215